title: Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy.
abstract: BACKGROUND
  Pegylated liposomal doxorubicin (PLD) is a highly efficient chemotherapeutic; however, it induces dermal side effects such as palmar-plantar erythrodysesthesia (PPE) in up to 80% of cases, probably by being emitted with the sweat onto the skin surface.
  
  
  OBJECTIVE
  The aim of the present study was to examine whether a topically applied ointment containing antioxidants with a high radical protection factor is able to prevent the formation of PPE.
  
  
  METHODS
  Twenty patients suffering from ovarian carcinoma and treated with PLD were observed.
  
  
  RESULTS
  60% of the patients tolerated the regular application of the cream and developed no PPE. The remaining 40% interrupted the application. Six of them developed PPE and resumed ointment application thereafter. In these cases the PPE disappeared or was strongly reduced.
  
  
  CONCLUSIONS
  The results of the observation clearly demonstrate that topical application of the ointment is an efficient strategy against the development of PPE during chemotherapy with PLD.
authors: Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors: Juergen
authors: J
authors: Lademann
authors: Anja
authors: A
authors: Martschick
authors: Franziska
authors: F
authors: Kluschke
authors: Heike
authors: H
authors: Richter
authors: Joachim W
authors: JW
authors: Fluhr
authors: Alexa
authors: A
authors: Patzelt
authors: Sora
authors: S
authors: Jung
authors: Radoslav
authors: R
authors: Chekerov
authors: Maxim E
authors: ME
authors: Darvin
authors: Norbert
authors: N
authors: Haas
authors: Wolfram
authors: W
authors: Sterry
authors: Leonhard
authors: L
authors: Zastrow
authors: Jalid
authors: J
authors: Sehouli
mesh_terms: D000368:Aged; D029969:Angelica; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects* / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use*; D028241:Camellia sinensis; D002277:Carcinoma / Q000188:drug therapy; D040503:Coffea; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D060831:Hand-Foot Syndrome / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D033641:Millettia; D009824:Ointments; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D012822:Silicon Dioxide / Q000737:chemistry
chemical_list: D000903:Antibiotics, Antineoplastic; D000975:Antioxidants; D009824:Ointments; D010936:Plant Extracts; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D012822:Silicon Dioxide; D004317:Doxorubicin